Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGWP.L Regulatory News (GWP)

  • There is currently no data for GWP

Director/PDMR Shareholding

19 Mar 2008 15:29

GW Pharmaceuticals PLC19 March 2008 For immediate release 19 March 2008 GW Pharmaceuticals plc ("the Company") Notification of Interests of Directors Following shareholder approval at yesterday's AGM of the GW Pharmaceuticals plcLong-Term Incentive Plan, the Company has granted the following awards toDirectors over the Company's ordinary shares ("Shares"). On 19 March 2008, the Company granted the following awards in the form ofnominal-cost options ("Awards") under the GW Pharmaceuticals plc Long-TermIncentive Plan: Name Number of Shares under Award Total number of Shares over which options / awards heldDr Geoffrey Guy 170,000 1,789,914Justin Gover 153,000 2,079,469David Kirk 137,000 2,273,136Dr Stephen Wright 140,000 1,177,180 The exercise price of the Awards is 0.1p per Share, the par value of the Shares. The Awards will ordinarily vest on 19 March 2011, subject to regulatory approvalof the Company's lead product, Sativex(R), being achieved in any one of the UK,France, Germany, Italy or Spain. Once vested, an Award may be exercised at anytime prior to the tenth anniversary of the date of grant. For further information please contact Adam George, Company Secretary &Financial Controller, GW Pharmaceuticals plc on 01980 557 000. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Dec 201611:15 amRNSAmerican Society of Epilepsy Annual Meeting
30th Nov 20161:00 pmRNSNotice of Q4 and year-end results
24th Nov 20167:30 amRNSHolding(s) in Company
22nd Nov 20161:00 pmRNSPresenting at Piper Jaffray Healthcare Conference
18th Nov 20169:31 amRNSHolding(s) in Company
11th Nov 20165:01 pmRNSHolding(s) in Company
10th Nov 201611:03 amRNSDirector/PDMR Shareholding
3rd Nov 20161:58 pmRNSDirector/PDMR Shareholding
3rd Nov 20167:50 amRNSHolding(s) in Company
3rd Nov 20167:47 amRNSHolding(s) in Company
2nd Nov 20165:05 pmRNSDirector/PDMR Shareholding
1st Nov 20169:58 amRNSDirector/PDMR Shareholding
31st Oct 20163:29 pmRNSHolding(s) in Company
31st Oct 20162:59 pmRNSTotal Voting Rights
31st Oct 20168:25 amRNSHolding(s) in Company
28th Oct 20164:58 pmRNSDirector Stock Trading Plan
28th Oct 20164:57 pmRNSDirector/PDMR Shareholding
26th Oct 20165:26 pmRNSDirector/PDMR Shareholding
25th Oct 20165:43 pmRNSDirector/PDMR Shareholding
21st Oct 20164:37 pmRNSPosting of Shareholder Circular
20th Oct 20163:30 pmRNSHolding(s) in Company
19th Oct 20167:00 amRNSIntention to Trade Exclusively on NASDAQ
7th Oct 201610:22 amRNSDirector Stock Trading Plan - Replacement
6th Oct 20166:01 pmRNSDirector Stock Trading Plan
30th Sep 20161:48 pmRNSTotal Voting Rights
26th Sep 201611:57 amRNSSecond Positive Phase 3 Trial for Epidiolex in LGS
14th Sep 20165:27 pmRNSDirector/PDMR Shareholding
7th Sep 201612:00 pmRNSPresenting at Morgan Stanley Healthcare Conference
31st Aug 201612:18 pmRNSTotal Issued Share Capital
17th Aug 20168:56 amRNSBlock listing Interim Review
9th Aug 201612:00 pmRNS3rd Quarter Results
9th Aug 201612:00 pmRNSNotification of Future Change to Board
2nd Aug 201612:00 pmRNSNotice of Results
29th Jul 201610:58 amRNSTotal Voting Rights
25th Jul 20167:57 amRNSHolding(s) in Company
21st Jul 201610:08 amRNSHolding(s) in Company
21st Jul 201610:04 amRNSHolding(s) in Company
19th Jul 20169:37 amRNSTotal Voting Rights
18th Jul 20164:15 pmRNSClosing of U.S. Public Offering Raising $289.8m
13th Jul 20167:00 amRNSUS Public Offering of ADSs Raising $252.0 Million
13th Jul 20167:00 amRNSProposed Public Offering of ADSs
1st Jul 20163:14 pmRNSHolding(s) in Company
1st Jul 20168:03 amRNSHolding(s) in Company
30th Jun 20163:22 pmRNSTotal Voting Rights
28th Jun 201612:14 pmRNSHolding(s) in Company
27th Jun 201612:07 pmRNSSecond Price Monitoring Extn
27th Jun 201612:02 pmRNSPrice Monitoring Extension
27th Jun 201612:00 pmRNSPositive Phase 3 Pivotal Trial Results
27th Jun 201610:00 amRNSHolding(s) in Company
23rd Jun 20167:30 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.